TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
B: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.


Options:
A: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg
C: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
D: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 350 mg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 350 mg SC | Arm Label: 700 mg IV; Type: EXPERIMENTAL; Interventions: Drug: 700 mg IV | Intervention Type: DRUG; Name: 700 mg IV; Assigned to Arm(s): 700 mg IV | Intervention Type: DRUG; Name: 350 mg SC; Assigned to Arm(s): 350 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Group 1: Approved q12w maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Arm Label: Group 2: Subject-tailored fixed-interval maintenance regimen; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 45 mg, Drug: Ustekinumab 90 mg, Drug: Placebo | Intervention Type: DRUG; Name: Ustekinumab 45 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Approved q12w maintenance regimen, Group 2: Subject-tailored fixed-interval maintenance regimen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.


Options:
A: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: ActiveTreatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): ActiveTreatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
D: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Chewing Gum on Small Bowel Transit Time: a Prospective Randomized Trial.
Brief Summary: The purpose of this study is to see if chewing sugarless chewing gum alters the time it takes for a capsule endoscopy to travel through the stomach and small bowel, and to see if more/less capsule endoscopes reach the large bowel.


Options:
A: Arm Label: Standard postoperative care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Chewing gum arm; Type: EXPERIMENTAL; Interventions: Other: Chewing gum | Intervention Type: OTHER; Name: Chewing gum; Assigned to Arm(s): Chewing gum arm
B: Arm Label: 1.; Type: ACTIVE_COMPARATOR; Interventions: Other: Trident sugarless chewing gum. | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Other: One control group (these do not chew gum). | Intervention Type: OTHER; Name: Trident sugarless chewing gum.; Assigned to Arm(s): 1. | Intervention Type: OTHER; Name: One control group (these do not chew gum).; Assigned to Arm(s): 2.
C: Arm Label: chewing gum; Type: EXPERIMENTAL; Interventions: Behavioral: gum chewing | Intervention Type: BEHAVIORAL; Name: gum chewing; Assigned to Arm(s): chewing gum
D: Arm Label: Treatment arm: coffee; Type: ACTIVE_COMPARATOR; Interventions: Other: Postoperative coffee | Arm Label: Water arm; Type: PLACEBO_COMPARATOR; Interventions: Other: water | Intervention Type: OTHER; Name: Postoperative coffee; Assigned to Arm(s): Treatment arm: coffee | Intervention Type: OTHER; Name: water; Assigned to Arm(s): Water arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Using Video Images in Advance Care Planning in Patients With Advanced Cancer
Brief Summary: To compare the decision making of subjects with advanced cancer having a verbal advance care planning discussion compared to subjects using a video.


Options:
A: Arm Label: Chest Pain Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Chest Pain Choice Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Chest Pain Choice Decision Aid; Assigned to Arm(s): Chest Pain Choice Decision Aid
B: Arm Label: video decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: video decision aid | Arm Label: Usual Care -- Verbal Description Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: video decision aid; Assigned to Arm(s): video decision aid
C: Arm Label: Solo Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Arm Label: Dyadic Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Intervention Type: BEHAVIORAL; Name: Skin Self Examination Information and ABCDE Rule; Assigned to Arm(s): Dyadic Learning, Solo Learning
D: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Using Video Images in Advance Care Planning in Patients With Advanced Cancer
Brief Summary: To compare the decision making of subjects with advanced cancer having a verbal advance care planning discussion compared to subjects using a video.


Options:
A: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
B: Arm Label: Communication training for cardiologists; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training for cardiologists. | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Communication training for cardiologists.; Assigned to Arm(s): Communication training for cardiologists | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
C: Arm Label: video decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: video decision aid | Arm Label: Usual Care -- Verbal Description Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: video decision aid; Assigned to Arm(s): video decision aid
D: Arm Label: Usual informed consent; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual, standard-of-care informed consent for chemotherapy | Arm Label: Investigational informed consent; Type: EXPERIMENTAL; Interventions: Other: Investigational informed consent for chemotherapy | Intervention Type: OTHER; Name: Investigational informed consent for chemotherapy; Assigned to Arm(s): Investigational informed consent | Intervention Type: OTHER; Name: Usual, standard-of-care informed consent for chemotherapy; Assigned to Arm(s): Usual informed consent

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial
Brief Summary: In the last years, important advances have been done in the treatment and prevention of esophageal variceal bleeding. Experts agree that the combination of pharmacological and endoscopic therapy should be the first line therapy in the acute bleeding episode; whereas TIPS (transjugular intrahepatic portosystemic shunt) is considered a rescue therapy. Nevertheless, some patients would require different therapies to act as a "bridge" until definitive therapy can be instituted. Balloon tamponade (using the Sengstaken tube) represents, up to now, the most widely used temporary "bridge" to TIPS. However, balloon tamponade is associated with a high incidence of serious adverse events. Recently, the use of self-expanding metal stents have been introduced in the treatment of acute variceal bleeding showing a very high hemostatic efficacy with no adverse events. The present study is directed to compare the efficacy free of adverse events and mortality of self-expanding metal stents vs balloon tamponade in patients with variceal bleeding refractory to medical and endoscopic therapy.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
B: Intervention Type: PROCEDURE; Name: Transjugular Intrahepatic Portosystemic Shunt (TIPS); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Distal Splenorenal Shunt; Assigned to Arm(s): N/A
C: Arm Label: Self-expandable esophageal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent | Arm Label: Sengstaken-Blakemore tube; Type: ACTIVE_COMPARATOR; Interventions: Device: Tamponade | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): Self-expandable esophageal stent | Intervention Type: DEVICE; Name: Tamponade; Assigned to Arm(s): Sengstaken-Blakemore tube
D: Arm Label: Hemospray; Type: EXPERIMENTAL; Interventions: Device: Hemospray, Drug: Octreotide, Biological: Blood transfusion, Drug: Ceftriaxone | Arm Label: Non Hemospray; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide, Biological: Blood transfusion, Drug: Ceftriaxone | Intervention Type: DEVICE; Name: Hemospray; Assigned to Arm(s): Hemospray | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Hemospray, Non Hemospray | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Hemospray, Non Hemospray | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): Hemospray, Non Hemospray

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice
Brief Summary: This quality improvement trial aims to evaluate whether giving patients information about their coronary heart disease risk via a computer kiosk in the doctors waiting room and providing primary care doctors with a personal digital device with a decision support tool to help with cholesterol management will improve cholesterol management compared to usual care.


Options:
A: Arm Label: Control (Usual Care); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Simplified cardiovascular disease management | Intervention Type: OTHER; Name: Simplified cardiovascular disease management; Assigned to Arm(s): Intervention
B: Arm Label: Multi-modal practice intervention; Type: N/A; Interventions: Behavioral: HeartAge intervention | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HeartAge intervention; Assigned to Arm(s): Multi-modal practice intervention
C: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
D: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice
Brief Summary: This quality improvement trial aims to evaluate whether giving patients information about their coronary heart disease risk via a computer kiosk in the doctors waiting room and providing primary care doctors with a personal digital device with a decision support tool to help with cholesterol management will improve cholesterol management compared to usual care.


Options:
A: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm
B: Arm Label: Multi-modal practice intervention; Type: N/A; Interventions: Behavioral: HeartAge intervention | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HeartAge intervention; Assigned to Arm(s): Multi-modal practice intervention
C: Arm Label: Clinical Decision Support for BUP; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Decision Support (CDS) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical Decision Support (CDS); Assigned to Arm(s): Clinical Decision Support for BUP
D: Arm Label: Facilitated Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Other: Facilitated Clinical Decision Support | Arm Label: Clinical Decision Support Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical Decision Support Only | Intervention Type: OTHER; Name: Facilitated Clinical Decision Support; Assigned to Arm(s): Facilitated Clinical Decision Support | Intervention Type: OTHER; Name: Clinical Decision Support Only; Assigned to Arm(s): Clinical Decision Support Only

Answer: B